FOR RELEASE, December 16, 2008

Trinity Biotech Receives CE Marking and Announces European Launch of Destiny Max

DUBLIN, Ireland (December 16, 2008)…. Trinity Biotech plc (NASDAQ: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the European Launch of its new high throughput haemostasis analyzer, the Destiny Max.

Trinity has today obtained CE marking of its Destiny Max analyzer and is launching the instrument in Europe and internationally with immediate effect. The target market for the instrument includes university hospitals, high throughput general hospitals, high volume commercial laboratories and reference laboratories. Key features of the Destiny Max include :

- The only high throughput instrument on the market that allows simultaneous and automated measurement of mechanical and optical clot detection
- Best in class graphical user interface and touch screen technology
- Most reliable cap piercing solution on the market

Commenting on the launch Ronan O' Caoimh, CEO, said "I am particularly pleased to announce the launch of Destiny Max which is without doubt the best haemostasis instrument offering available on the market today. The instrument will enable Trinity to target the high throughput segment of the laboratory based haemostasis market which represents approximately 50% of the overall market or US$500 million annually. The project has definitively proven our ability to integrate hardware, software and reagents into a new state-of-the art instrument platform that will exceed customer expectations. Initial sales of the instrument will take place this month to Japan, Italy and Ireland."

Forward-looking statements in this release are made pursuant to the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.

Trinity Biotech develops, acquires, manufactures and markets over 500 diagnostic products for the point-of-care and clinical laboratory segments of the diagnostic market. The broad line of test kits are used to detect infectious diseases, sexually transmitted diseases, blood coagulation disorders, and autoimmune diseases. Trinity Biotech sells worldwide in over 80 countries through its own salesforce and a network of international distributors and strategic partners. For further information please see the Company's website: www.trinitybiotech.com.

Contact *:*

Trinity Biotech plc
Ronan O' Caoimh
(353)-1-2769800
E-mail: **ronan@trinitybiotech.com**

Lytham Partners LLC
Joe Diaz, Joe Dorame & Robert Blum
602-889-9700